Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1F32GM143862-01
Grant search
Key facts
Disease
COVID-19Start & end year
2021.02023.0Known Financial Commitments (USD)
$79,386Funder
National Institutes of Health (NIH)Principal Investigator
INSTRUCTOR Claire ShappellResearch Location
United States of AmericaLead Research Institution
BRIGHAM AND WOMEN'S HOSPITALResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
SARS-CoV-2 causes a wide spectrum of illness ranging from asymptomatic infection to multiorgan failure and death. Patients infected with SARS-CoV-2 who develop organ dysfunction technically meet the Third International Consensus Definitions of Sepsis and Septic Shock, which define sepsis as a dysregulated host response to infection leading to life-threatening infection. Clinicians rarely frame severe COVID-19 as sepsis, however, despite the fact that doing so could help rapidly convey the seriousness of the condition and invoke existing hospital structures and management pathways to optimize care for this very ill subset of patients. At the same time, severe COVID-19 likely has unique features that differentiate it from routine bacterial sepsis as well as from other respiratory viruses. The overall objective of this proposal is to characterize the incidence and outcomes for COVID-19- associated sepsis, its risk factors, and how these compare to sepsis from influenza or bacterial infections. Our proposed project will leverage objective definitions of sepsis and organ dysfunction based on CDC's Adult Sepsis Event criteria, a large database with detailed electronic health record data from five hospitals, and a research group with extensive experience using big data to conduct innovative and impactful studies on epidemiology, diagnosis, prevention, and treatment of sepsis, pneumonia, and other healthcare-associated infections. In Aim 1 of our proposal, we will utilize state-of-the-art methods in sepsis surveillance to provide rigorous estimates of sepsis incidence in COVID-19 and enable evidence-based comparisons between outcomes and risk factors for sepsis due to COVID-19 versus influenza or bacterial infections. In Aim 2, we will incorporate patient demographics, comorbidities, vital signs, and laboratory test results available at the time of presentation in order to predict the development of sepsis in patients with COVID-19, allowing improved risk stratification of patients at the time of presentation and more efficient hospital resource allocation. The proposed work will have important public health impact by informing evidence-based comparisons of COVID-19, influenza, and bacterial sepsis to guide public policy. Characterizing the distinctive features of sepsis in COVID-19 could also help inform better risk stratification and management strategies and generate hypotheses into the pathophysiology of severe COVID-19. The award will also enable the candidate, Dr. Claire Shappell, to gain essential skills in data acquisition and analysis, predictive modeling, use of statistical analysis software, and grantsmanship, enabling her to achieve her long term objective of becoming an independently-funded physician-scientist with expertise in mining the increasingly abundant clinical and physiologic data available via electronic health records (EHRs) in order to characterize population trends and identify novel opportunities for care improvement in critical illness.